Glenmark Pharmaceuticals Pvt Ltd is headquartered in Mumbai, India and was established in 1977. Today, it is a leading player in the discovery of new molecules, both NCEs (new chemical entity) and NBEs (new biological entity), and it currently has seven molecules in various stages of clinical development and pre-clinical development. The company has a significant presence in branded generics markets across emerging economies, including India. Its subsidiary, Glenmark Generics Ltd has a fast growing and robust US generics business. The subsidiary also markets APIs to regulated and semi-regulated countries. Glenmark employs over 10,400 people in over 80 countries. It has 14 manufacturing facilities in four countries and has six research and development (R&D) centres.
Glenmark Pharmaceuticals: Innovating Newer Molecules
|2011||Wins Gold Patent Award in the categories of API Formulations and Export of Bulk Drugs by Pharmexcil|
|2010||Enters into exclusive licensing agreement with Par Pharmaceuticals|
|2008||Receives recognition by Forbes as one of the 'best under a billion dollar companies in Asia'|
|2007||Acquires Medicamenta, a marketing and manufacturing company in Czech Republic|
|2006||Signs out-licencing deal in discovery R&D with Merck KGaA, Germany|